MLN8054 sodium
Based on 10 publication(s) in Google Scholar
MLN8054 sodium is an Aurora A inhibitor with radiosensitivity-enhancing activity. MLN8054 sodium can activate the DNA double-strand break reaction of prostate cancer cells in in vitro experiments. The application of MLN8054 sodium is closely related to accumulation in the G2/M phase of the cell cycle and polyploid formation. In vivo experiments show that MLN8054 sodium can significantly delay the growth of prostate cancer tumors and promote tumor cell apoptosis when used in combination with radiotherapy.
For research use only. We do not sell to patients.
- CAS No.: 869366-15-4
- Formula: C25H14ClF2N4NaO2
- Molecular Weight:498.84
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) MLN8054 sodium
More- Cancer Res. 2017 Sep 15;77(18):4785-4796. [Abstract]
- Sci Transl Med. 2018 Jul 18;10(450):eaaq1093. [Abstract]
- PLoS Biol. 2020 Jun 9;18(6):e3000288. [Abstract]
- EMBO Rep. 2021 Jul 5;22(7):e51847. [Abstract]
- Comput Struct Biotechnol J. 2019 Feb 8:17:352-361. [Abstract]
- Mol Cell Endocrinol. 2025 Aug 28:609:112645. [Abstract]
- Anticancer Drugs. 2024 Jan 1;35(1):46-54. [Abstract]
- Patent. US20210299273A1.
- Technical University of Munich. 24.01.2018.
- J Biomol Screen. 2013 Oct;18(9):1062-71. [Abstract]
All Aurora Kinase Isoforms
More
Biological Activity
Chemical Information
-
CAS No. 869366-15-4
-
Molecular Weight 498.84
-
Formula C25H14ClF2N4NaO2
-
SMILES
O=C(C1=CC=C(NC2=NC(C3=C(C(C4=C(F)C=CC=C4F)=NC5)C=C(Cl)C=C3)=C5C=N2)C=C1)O[Na]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (10)
-
Journal Impact Factor
-
Most Recent
-
Cancer Res
2017 Sep 15;77(18):4785-4796. PMID: 28720575 -
Sci Transl Med
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]2018 Jul 18;10(450):eaaq1093. PMID: 30021885 -
PLoS Biol
2020 Jun 9;18(6):e3000288. PMID: 32516310 -
EMBO Rep
CK1-mediated phosphorylation of FAM110A promotes its interaction with mitotic spindle and controls chromosomal alignment. [Abstract]2021 Jul 5;22(7):e51847. PMID: 34080749 -
Comput Struct Biotechnol J
Unveiling the Kinomes of Leishmania infantum and L. braziliensis Empowers the Discovery of New Kinase Targets and Antileishmanial Compounds. [Abstract]2019 Feb 8:17:352-361. PMID: 30949306 -
Mol Cell Endocrinol
The N-terminal region of HASPIN regulates phosphorylation of AURKA and meiotic progression in spermatocytes. [Abstract]2025 Aug 28:609:112645. PMID: 40885374 -
Anticancer Drugs
2024 Jan 1;35(1):46-54. PMID: 37449977 -
-
-
J Biomol Screen
Differential determinants of cancer cell insensitivity to antimitotic drugs discriminated by a one-step cell imaging assay. [Abstract]2013 Oct;18(9):1062-71. PMID: 23788527
Purity & Documentation
References
[1]. Manfredi MG, et al. Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4106-11. [Content Brief]
[2]. Huck JJ, et al. MLN8054, an inhibitor of Aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo. Mol Cancer Res. 2010 Mar;8(3):373-84. [Content Brief]
[3]. MLN8054, a small molecule inhibitor of aurora kinase a, sensitizes androgen-resistant prostate cancer to radiation [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
MLN8054 sodium Related Classifications
HY-10180A Related Classifications
Powered by Bioz